Skip to main content

Travis Mickle

Equibles does not estimate personal net worth.

About Travis Mickle

Travis Mickle was last confirmed as CEO at Zevra Therapeutics, Inc. (ZVRA) in a filing dated May 12, 2022. Earlier roles on record: Board Member at Zevra Therapeutics, Inc. (ZVRA) until April 25, 2023. Zevra Therapeutics, Inc. reported in an 8-K filed March 30, 2023 that Travis Mickle resigned as director, effective April 25, 2023. The proxy statement of Zevra Therapeutics, Inc. reports total compensation of $3,593,438 for Travis Mickle in fiscal 2023, including a base salary of $186,520. Disclosed compensation is on record for 6 fiscal years. Travis Mickle has spoken on 12 earnings calls across 1 company, most recently for Zevra Therapeutics, Inc. on January 25, 2023. The companies whose calls Travis Mickle spoke on are classified in the Healthcare sector.

“to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.”
Zevra Therapeutics, Inc. Form 8-K, filed March 30, 2023 · Read the filing

Travis Mickle on recent calls

“So as far from our last update, we have not had a more formal interaction with the FDA as to the resubmission. And then which really answers the next part of your question as well, which is, no, the FDA hasn't seen the data yet.”
CEO, Zevra Therapeutics, Inc. Q4 FY2022 Earnings Call ·
“And thank you everyone for joining us again today. For those who are not familiar with KemPharm, I would like to give just a brief introductory statement. KemPharm is focused on the development and discovery of novel treatments for rare CNS and neurodegenerative disorders as well as lysosomal storage diseases.”
CEO, Zevra Therapeutics, Inc. Q3 FY2022 Earnings Call ·
“And thank you everyone for joining us again today. We are pleased to have Perry with us on our second quarter results call today. We'll also be providing some product development updates from myself as well as the typical financial update from LaDuane, our CFO.”
CEO, Zevra Therapeutics, Inc. Q2 FY2022 Earnings Call ·
“For those that aren't as familiar with KemPharm, I'll just give a brief introduction here and discuss our value proposition. KemPharm has historically been focused on the discovery and development of prodrugs.”
CEO, Zevra Therapeutics, Inc. Q1 FY2022 Earnings Call ·
“A little bit of an introduction into KemPharm for those who are new to us. I'd like to speak a little about our value proposition. KemPharm is an innovative company developing novel treatments in CNS and rare diseases.”
CEO, Zevra Therapeutics, Inc. Q4 FY2021 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Zevra Therapeutics, Inc. (ZVRA) $186,520 $3,593,438
2022 Zevra Therapeutics, Inc. (ZVRA) $590,186 $2,400,356
2021 Zevra Therapeutics, Inc. (ZVRA) $561,946 $2,657,059
2020 Zevra Therapeutics, Inc. (ZVRA) $530,450 $967,979
2019 Zevra Therapeutics, Inc. (ZVRA) $527,875 $1,360,174
2018 Zevra Therapeutics, Inc. (ZVRA) $512,500 $1,423,379

Recent activity